ICU Medical (NASDAQ:ICUI) Raised to “Buy” at Jefferies Financial Group

Jefferies Financial Group upgraded shares of ICU Medical (NASDAQ:ICUI) from a hold rating to a buy rating in a report released on Wednesday, Marketbeat reports. They currently have $200.00 price target on the medical instruments supplier’s stock.

Several other equities research analysts have also recently issued reports on the stock. KeyCorp lifted their target price on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Raymond James boosted their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $177.25.

ICU Medical Stock Performance

Shares of NASDAQ:ICUI opened at $161.64 on Wednesday. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. ICU Medical has a 1 year low of $86.80 and a 1 year high of $196.26. The firm has a market capitalization of $3.96 billion, a PE ratio of -35.37 and a beta of 0.62. The business’s 50 day moving average price is $171.12 and its 200-day moving average price is $150.98.

Insider Buying and Selling

In other news, COO Christian B. Voigtlander sold 1,962 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $169.08, for a total transaction of $331,734.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00. Following the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,973,261.12. The trade was a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,364 shares of company stock worth $6,869,878. Insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Franklin Resources Inc. increased its position in shares of ICU Medical by 99.3% during the third quarter. Franklin Resources Inc. now owns 11,708 shares of the medical instruments supplier’s stock valued at $2,111,000 after acquiring an additional 5,834 shares during the last quarter. Coldstream Capital Management Inc. purchased a new position in shares of ICU Medical during the 3rd quarter worth approximately $227,000. Geode Capital Management LLC increased its holdings in ICU Medical by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock valued at $99,687,000 after purchasing an additional 48,106 shares during the last quarter. Barclays PLC raised its position in ICU Medical by 15.6% in the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock valued at $10,790,000 after purchasing an additional 8,010 shares during the period. Finally, XTX Topco Ltd acquired a new position in ICU Medical during the third quarter worth $342,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.